Red Light Photobiomodulation and Topical Disinfectants

Surgical Site Infection Clinical Trial

Official title: The Effect of Red Light Photobiomodulation and Topical Disinfectants on the Nasal Microbiome

Status Completed

Clinical Trial Summary

The goal of this clinical trial is to evaluate the potential effects of photobiomodulation when used with topical disinfectants in the anterior nares of healthy adults.

Over a three week period, participants will have their anterior nares swabbed with methylene blue, chlorhexidine gluconate, or a combination of the two followed by 4 minutes of non-thermal red light treatment. The fourth week of consist of only red light treatment. Culture samples of the subjects nasal microbiome will be taken prior to treatment, immediately after treatment, 4-, 8-, 24-, and 48 hours after treatment.

Clinical Trial Description

This is an exploratory, single-center, open-label, single-arm study with microbiological endpoint using photobiomodulation (PBM) and topical disinfectants to determine the effect on the nasal microbiota.

The photobiomodulation system distributes about 700mW of light to each nostril using a 2-channel diode laser with non-thermal, red light. The topical disinfectants are methylene blue (0.01%) and chlorhexidine gluconate (0.25%). Following a pretreatment nasal culture, these two disinfectants will be administered into the patient's anterior nares followed by a two-minute light cycle. This process is repeated once more resulting in two treatments cycles (4-minutes total). Following this, nasal cultures are taken immediately and at 4-, 8-, 24-, and 48- hours. Broad spectrum and Staphylococcus spp. culturing of nasal swabs will be conducted. Swabs will also be submitted for Next Generation Sequencing to characterize the effect of light and disinfectants on the nasal microbiome. ;

Related Conditions & MeSH terms

• Communicable Diseases
• Cross Infection
• Healthcare Associated Infection
• Infections
• Nosocomial Infection
• Surgical Site Infection
• Surgical Wound Infection

• NCT number: NCT05797818
• Study type: Interventional
• Source: Ondine Biomedical Inc.
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 10, 2023
• Completion date: February 8, 2023